Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

A molecular case report: functional assay of tyrosine kinase inhibitors in cells from a patient's primary renal cell carcinoma.

Kulesz-Martin MF, Lagowski J, Olson S, Wortham A, West T, Thomas G, Ryan C, Tyner JW.

Cancer Biol Ther. 2013 Feb;14(2):95-9. doi: 10.4161/cbt.22960. Epub 2012 Nov 28.

2.

Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.

Gunningham SP, Currie MJ, Han C, Turner K, Scott PA, Robinson BA, Harris AL, Fox SB.

Cancer Res. 2001 Apr 1;61(7):3206-11.

3.

A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.

Suwaki N, Vanhecke E, Atkins KM, Graf M, Swabey K, Huang P, Schraml P, Moch H, Cassidy AM, Brewer D, Al-Lazikani B, Workman P, De-Bono J, Kaye SB, Larkin J, Gore ME, Sawyers CL, Nelson P, Beer TM, Geng H, Gao L, Qian DZ, Alumkal JJ, Thomas G, Thomas GV.

Sci Transl Med. 2011 Jun 1;3(85):85ra47. doi: 10.1126/scitranslmed.3002004.

6.
8.

A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy.

Turcotte S, Chan DA, Sutphin PD, Hay MP, Denny WA, Giaccia AJ.

Cancer Cell. 2008 Jul 8;14(1):90-102. doi: 10.1016/j.ccr.2008.06.004.

9.

von Hippel-Lindau tumor suppressor gene-dependent mRNA stabilization of the survival factor parathyroid hormone-related protein in human renal cell carcinoma by the RNA-binding protein HuR.

Danilin S, Sourbier C, Thomas L, Rothhut S, Lindner V, Helwig JJ, Jacqmin D, Lang H, Massfelder T.

Carcinogenesis. 2009 Mar;30(3):387-96. doi: 10.1093/carcin/bgn275. Epub 2008 Dec 4.

PMID:
19056930
10.

Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma.

Flaherty KT, Puzanov I.

Biochem Pharmacol. 2010 Sep 1;80(5):638-46. doi: 10.1016/j.bcp.2010.04.005. Epub 2010 Apr 9. Review.

PMID:
20382128
11.

The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.

Koochekpour S, Jeffers M, Wang PH, Gong C, Taylor GA, Roessler LM, Stearman R, Vasselli JR, Stetler-Stevenson WG, Kaelin WG Jr, Linehan WM, Klausner RD, Gnarra JR, Vande Woude GF.

Mol Cell Biol. 1999 Sep;19(9):5902-12.

12.

Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells.

Gunaratnam L, Morley M, Franovic A, de Paulsen N, Mekhail K, Parolin DA, Nakamura E, Lorimer IA, Lee S.

J Biol Chem. 2003 Nov 7;278(45):44966-74. Epub 2003 Aug 27.

13.

Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma.

Joshi S, Singh AR, Durden DL.

Cancer Chemother Pharmacol. 2015 Mar;75(3):595-608. doi: 10.1007/s00280-014-2639-x. Epub 2015 Jan 13.

PMID:
25578041
14.

Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.

Golshayan AR, Brick AJ, Choueiri TK.

Future Oncol. 2008 Feb;4(1):85-92. doi: 10.2217/14796694.4.1.85. Review.

PMID:
18241003
15.

The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy.

Clark PE.

Kidney Int. 2009 Nov;76(9):939-45. doi: 10.1038/ki.2009.296. Epub 2009 Aug 5. Review.

16.

Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins.

Rohan SM, Xiao Y, Liang Y, Dudas ME, Al-Ahmadie HA, Fine SW, Gopalan A, Reuter VE, Rosenblum MK, Russo P, Tickoo SK.

Mod Pathol. 2011 Sep;24(9):1207-20. doi: 10.1038/modpathol.2011.80. Epub 2011 May 20.

17.

Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.

Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny-Baron G, Marmé D.

Cancer Res. 1996 May 15;56(10):2299-301.

18.

Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma.

Turcotte S, Desrosiers RR, Beliveau R.

Am J Physiol Renal Physiol. 2004 Feb;286(2):F338-48. Epub 2003 Oct 28.

PMID:
14583436
19.
20.

Supplemental Content

Support Center